● Milestone Pharmaceuticals is a biopharmaceutical company focused on cardiovascular conditions, led by etripamil, a calcium channel blocker delivered as a nasal spray for paroxysmal supraventricular tachycardia, or PSVT, a rapid heart-rhythm disorder.
Before reading anything into a double-digit percentage swing, it is worth knowing what actually sits behind the ticker. Lotus Pharmaceuticals, Inc (OTC: LTUS) is not a conventional, exchange-listed operating company but a sub-penny stock trading on the OTC market and described by data providers …
MabCure, Inc (OTC:MBCI) is the kind of obscure micro-cap that rarely surfaces outside of ticker screens, yet its focus, antibody-based early cancer detection, touches one of medicine's most sought-after goals. The reality behind MBCI is far more modest: a tiny development-stage company that has …
Mustang Bio, Inc. (NASDAQ: MBIO), a cell-and-gene-therapy developer, sits in a precarious spot on Nasdaq: its shares trade well below $1 and the company is racing a listing-compliance clock. The stock eased modestly in recent trading, but the more consequential backdrop is a Nasdaq …
● Few small-cap biotech names capture the tension between clinical promise and financial fragility as vividly as Moleculin Biotech.
A quote of a hundred-thousandth of a cent tends to tell its own story. Medican Enterprises Inc (OTC:MDCN) trades on the over-the-counter market at effectively nothing, and the flat tape reflects a company that stopped reporting to regulators years ago rather than one poised …
Medicus Pharma Ltd (NASDAQ: MDCX) enters the autumn as a company mid-reinvention. The clinical-stage drug developer, which trades below 20 cents and carries a market value of only about $11 million, has begun repositioning itself as a precision oncology-led biotechnology business. With a fresh …
● In fact, the recent news flow has been positive: alongside the strong quarter, Lake Street raised its price target on LENSAR to $13 from $10 on 20 August while maintaining a bullish stance.
● The modest positive session in the original framing is a price move, not a discrete catalyst; the meaningful driver is the pendingAcquisitionitself.
Lantern Pharma has spent 2026 leaning hard into a pitch that blends oncologyDrug Developmentwith artificial intelligence, and the small-cap has generated a steady stream of announcements. Yet the stock has drifted lower, trading near $1.77 in early September with a marketCapitalizationaround $23 million. For …